Tamoxifen 20 PCH

DRUG2 trials

Sponsors

Genentech Inc., F. Hoffmann-La Roche AG

Conditions

Estrogen Receptor (ER)-PositiveEstrogen Receptor-PositiveHER2-NegativeHER2-Negative Early Breast CancerLocally Advanced or Metastatic Breast Cancer previously treated with a CDK4/6 inhibitor and endocrine therapy

Phase 3

A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared with the Physician’s Choice of Endocrine Therapy Plus Everolimus in Patients with Estrogen Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer

Active, not recruitingCTIS2023-506821-12-00

Genentech Inc.Estrogen Receptor (ER)-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer previously treated with a CDK4/6 inhibitor and endocrine therapy

Start: 2023-10-12Target: 59Updated: 2025-12-17

A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared with Physician’s Choice of Adjuvant Endocrine Monotherapy in Patients with Estrogen Receptor-Positive, Her2-Negative Early Breast Cancer

Active, not recruitingCTIS2023-507172-44-00

F. Hoffmann-La Roche AGEstrogen Receptor-Positive, HER2-Negative Early Breast Cancer

Start: 2021-09-10Target: 1482Updated: 2025-11-25